Skip to main content

Table 4 Multivariate analysis as a function of radiated site

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Extracranial Radiation (n = 13,586) Intracranial Radiation (n = 8624)
Hazard Ratio 95% Confidence Interval p-value Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref < 0.0001 1.00 Ref < 0.0001
Female 0.85 0.81–0.89 0.82 0.78–0.86
Age 18–59 1.00 Ref 0.087 1.00 Ref < 0.0001
60–69 0.98 0.94–1.03 1.10 1.04–1.16
70–79 1.00 0.95–1.05 1.27 1.19–1.35
80+ 1.10 1.01–1.20 1.43 1.24–1.64
Comorbidity 0 1.00 Ref 0.002 1.00 Ref < 0.0001
1 1.04 0.99–1.08 1.09 1.03–1.15
> 2 1.12 1.05–1.20 1.25 1.15–1.36
Histology Adenocarcinoma 1.00 Ref < 0.0001 1.00 Ref < 0.0001
Non-adenocarcinoma 1.09 1.05–1.14 1.18 1.13–1.25
Race White 1.00 Ref < 0.0001 1.00 Ref < 0.0001
Non-white 0.88 0.83–0.92 0.86 0.80–0.92
Insurance Uninsured 1.00 Ref 0.753 1.00 Ref 0.533
Insured 1.02 0.92–1.12 1.04 0.93–1.16
Facility Type Academic 1.00 Ref < 0.0001 1.00 Ref < 0.0001
Nonacademic 1.11 1.07–1.16 1.21 1.15–1.27
Systemic Therapy Chemotherapy 1.00 Ref 0.002 1.00 Ref < 0.0001
Immunotherapy 0.90 0.85–0.96 0.83 0.77–0.90
Radiation EBRT 1.00 Ref < 0.0001 1.00 Ref < 0.0001
SRT 0.51 0.45–0.58 0.62 0.58–0.66